|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Pluristem Therapeutics (PSTI)'s PLX Cells Show Efficacy in Treating Lung Disease
7/31/2012 9:34:48 AM
HAIFA, Israel, July 31, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced the results of new preclinical tests that show its PLacental eXpanded (PLX) cells may be effective in reducing pulmonary fibrosis and improving lung function in a group of diseases collectively called interstitial lung disease (ILD). ILD includes the pulmonary insults occurring in the lung following its exposure to drugs, radiation or toxic chemicals and the pulmonary complications of systemic autoimmune diseases. More than 200,000 people have been diagnosed with ILD in the United States, and nearly five million people have been diagnosed worldwide. It is estimated that more than 40,000 patients die each year from ILD.
|
|
|
|
|
|
|
|
|
|
|